Sangamo Therapeutics

Yahoo Finance • last month

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight

The dynamics of the hemophilia A market are expected to change mainly due to the increase in prevalence and the launch of upcoming therapies such as Mim8 (Novo Nordisk), DTX201 (Pebocotocogene camaparvovec, BAY2599023 [Ultragenyx Pharmaceu... Full story

Yahoo Finance • last month

Sangamo rises as FDA grants Fast Track status to neuropathic pain asset

[FDA headquarters in Washington DC.] JHVEPhoto * Sangamo Therapeutics (SGMO [https://seekingalpha.com/symbol/SGMO]) is up ~16% in premarket trading Tuesday after announcing that ST-503, its candidate for intractable pain due to small fi... Full story

Yahoo Finance • last month

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Gain Friday Afternoon

Health care stocks were higher Friday afternoon, with the NYSE Health Care Index rising 2.5% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling subm... Full story

Yahoo Finance • 2 months ago

Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway

Earnings Call Insights: Sangamo Therapeutics (SGMO) Q3 2025 MANAGEMENT VIEW * CEO Alexander Macrae highlighted continued advancement of the clinical and preclinical pipeline, with a focus on managing cash resources. Macrae stated, "In... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.11, revenue of $0.6M misses by $33.8M

* Sangamo Therapeutics press release [https://seekingalpha.com/pr/20296724-sangamo-therapeutics-reports-recent-business-highlights-and-third-quarter-2025-financial] (SGMO [https://seekingalpha.com/symbol/SGMO]): Q3 GAAP EPS of -$0.11 mis... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for... Full story

Yahoo Finance • 2 months ago

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the... Full story

Yahoo Finance • 4 months ago

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR st... Full story

Yahoo Finance • 5 months ago

Sangamo Therapeutics Inc (NASDAQ:SGMO) Reports Q2 2025 Earnings: Revenue Misses but Narrower-Than-Expected Loss

Sangamo Therapeutics Inc (NASDAQ:SGMO [https://www.chartmill.com/stock/quote/SGMO]) reported its second-quarter 2025 financial results, missing revenue estimates but delivering a narrower-than-expected loss per share. The clinical-stage bi... Full story

Yahoo Finance • 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics, Inc. Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in... Full story

Yahoo Finance • 6 months ago

H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data

Sangamo Therapeutics Inc. (NASDAQ:SGMO) ranks among the best CRISPR stocks to buy. Following the release of Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s top-line findings from its Phase 1/2 STAAR study, H.C. Wainwright reaffirmed its Buy rati... Full story

Yahoo Finance • 7 months ago

Sangamo stock holds Buy rating at H.C. Wainwright on Fabry therapy data

Investing.com - H.C. Wainwright reiterated its Buy rating and $10.00 price target on Sangamo BioSciences (NASDAQ:SGMO) following the company’s announcement of top-line results from its Phase 1/2 STAAR trial. Want deeper insights into biote... Full story

Yahoo Finance • 7 months ago

Sangamo rises after trial data for Fabry disease therapy

[Book with diagnosis Fabry disease and pills. Medical concept.] designer491 Shares of Sangamo Therapeutics (NASDAQ:SGMO [https://seekingalpha.com/symbol/SGMO]) traded higher in the premarket on Tuesday after the company announced positive... Full story

Yahoo Finance • 7 months ago

Sangamo reports positive results for Fabry disease gene therapy

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a clinical-stage biotechnology company with a market capitalization of $103 million and trailing twelve-month revenue of $64 million, announced positive topline results from its... Full story

Yahoo Finance • 8 months ago

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Upfront License Fee: Received $18 million from Eli Lilly for the first target under the STAC-BBB license agreement. Potential Milestone Payments: Eligible to earn up to $1.4 billion in additional license target fees and milestone payments... Full story

Yahoo Finance • 2 years ago

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participant... Full story

Yahoo Finance • 3 years ago

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

https://cdn.benzinga.com/files/images/story/2023/03/20/sgmo_logo_light__df15263084666d45f8f072d9581b42da.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Two big-name partners have walked away from partnerships with Sangamo Therapeutic... Full story

Yahoo Finance • 4 years ago

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

BRISBANE, Calif., April 28, 2022--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the mark... Full story